ClinicalTrials.gg
TerminatedNCT03887442EXTAXUpdated Jan 7, 2021Results posted

Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy

A Phase 2 interventional study of Paclitaxel and Cetuximab + Paclitaxel in Head and Neck Cancer, sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Terminated. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-07.

Sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
low recruitment rate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 86 studies testing cetuximab in Head and Neck Neoplasms — 2 open to participants now, 7 under way, 2 of them phase 3. Cetuximab · Head and Neck Neoplasms.

Enrollment
63rd of 84
17 · median 37
Started
2011
with 6 others
Phase 2
52 of 86
1 open now
Registered
54th of 86
by date
Lead sponsor
2 of 86
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Among the 86 studies testing cetuximab in Head and Neck Neoplasms, this one is the 63rd largest by enrollment of the 84 interventional ones that give a count, is one of 7 that started in 2011, is one of 52 in phase 2, and was the 54th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

2 of the 86 studies testing cetuximab in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cetuximab in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

Treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) after progression to first line EXTREME-type treatment in patients undergoing maintenance treatment with cetuximab.

03

Conditions studied

  • Head and Neck Cancer

Keywords

  • Head and Neck Cancer
  • Cetuximab
  • Erbitux
  • Paclitaxel
  • Extreme
  • Metastatic
  • Recurrent
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed the
  2. Age ≥ 18 and \< 75 y
  3. (Eastern Cooperative Oncology Group)performance status: 0-1
  4. of at least 12 weeks
  5. Histological or cytological confirmation of head \& neck squamous cell carcinoma with localization in larynx, oropharynx, oral cavity or hypopharynx.
  6. Having received at least 2 cycles of EXTREME-type chemotherapy (cisplatin or carboplatin + fluoropyrimidines + cetuximab) and being in maintenance phase with cetuximab because of having reached CR (Complete response), PR (Partial response) or SD (Stable disease) to said treatment
  7. At least one measureable lesion by CT scan or MRI
  8. Adequate bone marrow, liver and kidney function, according to:

    • (Hemoglobin) ≥ 9.0 g/dl
    • 100,000/mm3
    • (Absolute Neutrophil Count) ≥ 1,500/mm3
    • Total ≤ 2 times the UNL
    • /ALT and SGOT/AST ≤ 3 x UNL (Upper normal limit)
    • Alkaline phosphatase ≤ 2.5 x UNL
    • Serum creatinine ≤ 1.5 times the or > 50 ml/min
  9. Adequate nutritional status: weight loss \< 20% in relationship to usual weight or albumin ≥ 35 g/l, in the last 12 w
  10. Seric calcium adjusted to albumine lower or equal to 1,25 UNL.
  11. Toxicity, due to previous treatment received, resolved to grade 1, before enrolment in the study
  12. Women of should have a (-)ve pregnancy test in serum or urine,7 d before randomization. women should have remained amenorrheic for at least 12 m. Furthermore, all men as well as women who participate in this study should use effective methods beginning with the signing of the informed consent form and up to at least 6 m after the completion of the study or of the last dose, whichever occurs first

Exclusion criteria

Exclusion Criteria:

  1. Treatment for recurrent and/or disease other than the EXTREME- type (cisplatin or carboplatin + fluoropyrimidines + cetuximab)
  2. Non- as only evidence of disease
  3. Nasopharyngeal carcinoma
  4. Clinical or radiographic evidence of
  5. Having history of or presenting cardiovascular disease, such as, but not limited to, congestive heart failure, ≥ grade II of the , severe cardiac arrhythmias that require medication, or ≥ grade II peripheral vascular disease. Furthermore, those patients who have suffered myocardial infarction or unstable angina in the year prior to the onset of the study treatment or a recent onset angina in the last 3 m will also be excluded
  6. History of or current presence of grade >1 peripheral neuropathy
  7. History of active neurological disease
  8. History of uncontrolled convulsive episode
  9. Current ≥ 2 grade infection
  10. Known infection by or chronic infection by or HBC or presence of uncontrolled and severe intercurrent infections or other severe and uncontrolled concomitant diseases
  11. History of uncontrolled diabetes, uncontrolled HBP or hepatic condition.
  12. History of pulmonary fibrosis, acute pulmonary damage or interstitial pneumonia
  13. Any antineoplastic treatment within the 4 w prior to the randomization period
  14. History of another neoplastic disease during the last 5 y, with the exception of cured "in situ" basal cell ca.skin carcinoma, "in situ" ca.bladder, "in situ" ca.cervix and "in situ" ca.prostate
  15. Known allergy or suspicion of allergy or to any component of cetuximab or paclitaxel
  16. Previous treatment with monoclonal antibodies or other signal transduction inhibitors or EGFR-targeted treatment (Except for previous treatment with cetuximab)
  17. Known drug abuse (exception Alcoholism)
  18. Any important and uncontrolled medical, psychological, psychiatric, geographic or social problem that may interfere in the participation of the subject in the study and that does not allow for adequate follow-up and compliance with the protocol and evaluation of the study results
  19. Women who are pregnant or in breast-feeding period
  20. Use of any new drug within the 4 w prior to randomization
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Active comparator
    Paclitaxel

    Paclitaxel 80 mg/m2 may be infused, intravenously, every week.

    Drug: Paclitaxel

  • Experimental
    Cetuximab + Paclitaxel

    Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.

    Drug: Cetuximab + Paclitaxel

Interventions

  • Paclitaxel 80 mg/m2 may be infused, intravenously, every week.

  • DrugCetuximab + Paclitaxel

    Drug pages: CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    The primary endpoint was to select the most effective treatment arm based on the progression-free survival (PFS) reached in each treatment arm. This was defined as the time elapsed from inclusion in the study until the date when disease progression or death (for any cause) was documented.

    Time frame: Through study completion. The study was prematurely closed at 19 months due to lack of accrual. The primary endopoint was not analyzed.

Secondary outcomes

  1. Overall Survival

    Calculate overall survival (OS) in both arms

    Time frame: Through study completion. The study was prematurely closed at 19 months due to lack of accrual. The secondary endopoint was not analyzed.

  2. Percentage of Objective Response

    Calculate the percentage of objective responses (OR), following the new RECIST criteria, obtained in both arms

    Time frame: Through study completion. The study was prematurely closed at 19 months due to lack of accrual. Neither the primary nor the secondary endopoints were analyzed.

  3. Participants With Adverse Events

    To perform a descriptive analysis of the adverse events observed in the patients included in the study. Further analysis could not be performed due to early closure of this study due to lack of accrual. Adverse events were registered from study entry until 60 days after receiving the last dose of study drug.

    Time frame: The duration of the study (Nineteen months) and until the last patient included completed one year of follow up / died or was lost to FU. Adverse events were registered from study entry until 60 days after receiving the last dose of study drug.

  4. Treatment Compliance

    Evaluate treatment compliance rate in both treatment arms, in order to analyze it, the dose intensity would be calculated as the quantity of each of the administered study drugs per unit of time (mg/m2/week) regardless of the treatment arm. To analyze the relative dose intensity, the dose of each administered drug will be divided per a unit of time and the planned quantity of each drug according to the doses described in the protocol.

    Time frame: 3 years

07

Results

Posted Dec 9, 2020
Limitations and caveats
After 19 mos. the study was prematurely closed due to lack of accrual, only 17 pts were included. It was not possible to analyze the 1ry nor the 2ry endpoints of the study. A safety analysis was performed.

Participant flow

The study was carried out in 10 academic medical centers in Spain. First patient in was on 16-February-2011 and the study was closed (last patient in) on 02-October-2012.

Participant flow — Overall Study
MilestonePaclitaxelCetuximab + Paclitaxel
Started98
Completed88
Not completed10
Withdrew: Adverse event10

Outcome measures

PrimaryProgression Free Survival (PFS)

The primary endpoint was to select the most effective treatment arm based on the progression-free survival (PFS) reached in each treatment arm. This was defined as the time elapsed from inclusion in the study until the date when disease progression or death (for any cause) was documented.

Time frame:
Through study completion. The study was prematurely closed at 19 months due to lack of accrual. The primary endopoint was not analyzed.

No measurements were reported for this outcome.

SecondaryOverall Survival

Calculate overall survival (OS) in both arms

Time frame:
Through study completion. The study was prematurely closed at 19 months due to lack of accrual. The secondary endopoint was not analyzed.

No measurements were reported for this outcome.

SecondaryPercentage of Objective Response

Calculate the percentage of objective responses (OR), following the new RECIST criteria, obtained in both arms

Time frame:
Through study completion. The study was prematurely closed at 19 months due to lack of accrual. Neither the primary nor the secondary endopoints were analyzed.

No measurements were reported for this outcome.

SecondaryParticipants With Adverse Events

To perform a descriptive analysis of the adverse events observed in the patients included in the study. Further analysis could not be performed due to early closure of this study due to lack of accrual. Adverse events were registered from study entry until 60 days after receiving the last dose of study drug.

Time frame:
The duration of the study (Nineteen months) and until the last patient included completed one year of follow up / died or was lost to FU. Adverse events were registered from study entry until 60 days after receiving the last dose of study drug.
Reported as:
Number · participants
Participants With Adverse Events
participantsPaclitaxelCetuximab + Paclitaxel
Participants With Adverse Events98
SecondaryTreatment Compliance

Evaluate treatment compliance rate in both treatment arms, in order to analyze it, the dose intensity would be calculated as the quantity of each of the administered study drugs per unit of time (mg/m2/week) regardless of the treatment arm. To analyze the relative dose intensity, the dose of each administered drug will be divided per a unit of time and the planned quantity of each drug according to the doses described in the protocol.

Time frame:
3 years

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events were collected across the duration of study treatment. This was during the 19 months the study was open until 60 days after the last patient being treated received the last dose of study drug.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paclitaxel6/9 (66.7%)4/9 (44.4%)9/9 (100%)
Cetuximab + Paclitaxel4/8 (50%)4/8 (50%)8/8 (100%)
Most frequent serious events
Most frequent serious events
EventPaclitaxelCetuximab + Paclitaxel
VomitingGastrointestinal disorders0/91/8
BronchospasmRespiratory, thoracic and mediastinal disorders0/91/8
Lung infectionInfections and infestations0/91/8
Abdominal painGastrointestinal disorders0/91/8
PneumoniaInfections and infestations0/91/8
InfectionInfections and infestations0/91/8
Fracture of humerusInjury, poisoning and procedural complications1/90/8
Pneumococcal pneumoniaInfections and infestations1/90/8
Mouth bleedingGastrointestinal disorders1/90/8
DyspneaRespiratory, thoracic and mediastinal disorders1/90/8
Most frequent other events
Showing 10 of 89
Most frequent other events
EventPaclitaxelCetuximab + Paclitaxel
Mucosal inflammationGeneral disorders3/96/8
AstheniaGeneral disorders5/95/8
AlopeciaSkin and subcutaneous tissue disorders4/92/8
RashSkin and subcutaneous tissue disorders1/93/8
ConstipationGastrointestinal disorders1/93/8
HypomagnesemiaMetabolism and nutrition disorders0/93/8
DyspneaRespiratory, thoracic and mediastinal disorders3/90/8
ParesthesiaNervous system disorders3/90/8
Palmoplantar Erythrodysesthesia SyndromeSkin and subcutaneous tissue disorders3/90/8
DysphagiaGastrointestinal disorders2/92/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)PaclitaxelCetuximab + PaclitaxelTotal
Mean63.16 ± 7.2558.48 ± 8.7660.96 ± 8.11
Sex: Female, Male
Sex: Female, Male(Participants)PaclitaxelCetuximab + PaclitaxelTotal
Female123
Male8614
Region of Enrollment
Region of Enrollment(Participants)PaclitaxelCetuximab + PaclitaxelTotal
Spain9817
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2011 to primary completion in Oct 2012, 19 months.

Results were first posted in Dec 2020, 8 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2011
First posted
Mar 25, 2019
StartActual
Feb 16, 2011
Primary completionActual
Oct 2, 2012
CompletionActual
Oct 2, 2012
Results first posted
Dec 9, 2020
Last update
Jan 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03887442
Lead sponsor
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Collaborators
Merck Sharp & Dohme LLC, Pivotal S.L.
Responsible party
Sponsor
First posted
Mar 25, 2019
Start date
Feb 16, 2011
Primary completion
Oct 2, 2012
Completion
Oct 2, 2012
Results posted
Dec 9, 2020
Last update
Jan 7, 2021

Study contacts

Ricard Mesía, MD
principal investigator · Institut Català d´Oncologia-Duran i Reynals
Juan J. Grau, MD
principal investigator · Hospital Clinic of Barcelona
Elvira del Barco, MD
principal investigator · University of Salamanca
Ruth Vera, MD
principal investigator · Complejo Hospitalario de Navarra

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Paclitaxel

Start the discussion